Skip to main content

Elafibranor

Pronunciation: elle-a-fib-ran-or
Generic name: elafibranor
Brand name: Iqirvo
Dosage form: oral tablet (80 mg)
Drug class: Miscellaneous metabolic agents

Medically reviewed by Carmen Pope, BPharm. Last updated on Apr 28, 2025.

What is elafibranor?

Elafibranor is used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well to UDCA, or used alone in patients unable to tolerate UDCA. It is an oral tablet that is taken once daily.

The brand name of elafibranor is Iqirvo, and it is made by Ipsen Biopharmaceuticals, Inc. There is no generic.

Elafibranor (Iqirvo) gained FDA approval on 10 June 2024 under the accelerated approval designation. Continued approval may be contingent on a positive clinical benefit in reducing alkaline phosphatase (ALP), with no increases in liver toxicity, being found in further clinical trials.

Mechanism

Elafibranor (Iqirvo) is a dual agonist of PPAR-alpha and PPAR-delta receptors. These receptors help regulate lipid and glucose metabolism, mitochondrial fatty acid metabolism, and oxidative stress. Elafibranor works by activating these receptors, reducing inflammation, improving bile acid metabolism, and reducing bile acid toxicity in patients with PBC. 

Clinical trials report that patients treated with elafibranor experienced a greater reduction in mean ALP within 4 weeks of treatment that was generally maintained through week 52.

Elafibranor belongs to the drug class called peroxisome proliferator-activated receptor (PPAR) agonists.

Side effects

The most common side effects of elafibranor are:

Serious side effects and warnings

Elafibranor can cause the following serious side effects:

Tell your healthcare provider right away if you have any of the following symptoms during treatment with elafibranor and they are severe or do not go away:

May cause harm to an unborn baby. If you are a female with the ability to become pregnant, your healthcare provider may conduct a pregnancy test before prescribing elafibranor.

Your healthcare provider may tell you to stop taking elafibranor temporarily or permanently if there are changes to either your liver tests or CPK levels. 

It is not known if elafibranor is safe and effective in children under 18 years of age.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking

Do not take elafibranor if you have signs or symptoms of advanced liver disease (decompensated cirrhosis).

Before taking elafibranor, tell your healthcare provider about all of your medical conditions, including if you:

Your healthcare provider should check for muscle pain or weakness before you start taking elafibranor. Tell your healthcare provider right away if you have new and/or severe muscle pain or muscle weakness. 

Pregnancy

Elafibranor can harm your unborn baby. You should not become pregnant during treatment with elafibranor.

Pregnancy Safety Study. If you become pregnant while taking elafibranor, tell your healthcare provider right
away. There is a pregnancy safety study for women who become pregnant while taking this medicine. Talk to your
healthcare provider about providing information to the pregnancy safety study. The purpose of this
study is to collect information about your health and your baby’s health. You or your healthcare provider can
report your pregnancy by calling 1-855-463-5217 or visiting https://www.ipsen.com/contact-us/

Females who can become pregnant:

Breastfeeding

It is not known if elafibranor passes into your breast milk. Do not breastfeed while taking elafibranor and for 3 weeks after the last dose. Talk with your healthcare provider about the best way to feed your baby if you take elafibranor.

How is elafibranor administered?

Take elafibranor exactly as your healthcare provider tells you to.

If you take a bile acid binding resin (such as cholestyramine or colestipol), take elafibranor at least 4 hours before or 4 hours after you take your bile acid binding resin.

Your healthcare provider will monitor your liver function while you are being treated with elafibranor and may adjust or discontinue treatment if you have evidence of liver toxicity or decompensated cirrhosis.

Dosing information

Adult dose for PBC: elafibranor 80 mg 1 time a day.

What happens if I miss a dose?

If you miss a dose of elafibranor, take the dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your usual dosing schedule. Do not double up on doses.

What happens if I overdose?

If you take too much elafibranor, call your healthcare provider or get emergency medical help right away.

What other drugs will affect elafibranor?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Elafibranor can affect the way certain medicines work. Especially tell your healthcare provider if you take:

This is not a complete list of interactions. Talk to your healthcare provider or see the Iqirvo (elafibranor) Package Insert for a full list.

Does elafibranor interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Store at room temperature between 15°C to 30°C (59°F to 86°F) in the original package (bottle and carton) to protect from moisture and light.

Keep out of the reach of children.

Ingredients

Elafibranor is only available as the brand Iqirvo.

Active ingredient: elafibranor

Inactive ingredients: colloidal silica dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and povidone.

Film coating: iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Available as 80 mg tablets.

Manufacturer

Elafibranor is manufactured by Ipsen Biopharmaceuticals, Inc., under the brand name Iqirvo. Their global headquarters are in Paris, France.

Genfit was the original developer of elafibranor, but Ipsen acquired the exclusive worldwide license rights to develop and commercialize elafibranor from Genfit in July 2023.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.